Skip to content
etf.net

Launched · SEC filings

Virtus Biotech ETF

BBPNYSE ArcaVirtusA

$103.41−1.12 (−1.07%)

As of Nov 10, 2026, 10:58 AM ET

A74/ 100

Rank 4 of 17 in Biotech & Genomics

A74/100Rank 4 of 17inBiotech & Genomics
Intraday session: down, 19 prints from 104.53 to 103.41. Range 103.41 to 104.73. Use the arrow keys to read each point.103.75104.00104.25104.7510 AM12 PM2 PM4 PM
Expense ratio
0.34%
Fund size
$133M
1Y total return
+41.2%
Yield · Last 12 months
0.00%
Holdings
66
Avg volume · 30D
11.7K sh
52W range
low $73.97high $110.05
Launched
Filings
SEC EDGAR

The ETF.net BBP Grade

A

Score 74 out of 100

Category
Biotech & Genomics⁠
Rank
4 of 17
Six-pillar profile for BBP. Scores out of 100: Cost 94, Risk 66, Mission 83, Tradability 29, Holdings 82, Durability 56. Strongest: Cost (94). Weakest: Tradability (29). Leans toward Cost.

Score 74 of 100 falls in the A band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A94 out of 100
    Rank 2 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    A83 out of 100
    Rank 5 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B66 out of 100
    Rank 8 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D29 out of 100
    Rank 13 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    A82 out of 100
    Rank 3 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B56 out of 100
    Rank 8 of 17

Our read on BBP

ETF.net Research

In short

ABiotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

Stated mandate

The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

Why people hold it

  • The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
  • 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
  • Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
  • One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

Worth knowing

  • Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
  • Income is not the point here. The fund has not been paying distributions, so the return story is price.
  • An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

BBP Holdings

Holdings pillarA82 out of 100Rank 3 of 17 in Biotech & Genomics
Asset class
Stocks
Holdings
66
Top-10 weight
28%
Largest holding
MRNA6.7%

Sectors

  • Health Care100.0%

Geography

  • United States94.99%
  • China1.97%
  • United Kingdom1.71%
  • Switzerland1.33%
The fund’s holdings, weight-ordered — page 1 of 5.
#TickerCompanyWeight %SharesMarket valueHeld by ETFs
1MRNAModerna Inc6.70%35,124$8.93M305
2XERSXeris Biopharma Holdings Inc2.95%258,184$3.92M68
3VSTMVerastem Inc2.70%427,577$3.6M40
4IOVAIovance Biotherapeutics Inc2.59%429,672$3.45M97
5OMEROmeros Corp2.55%200,694$3.4M58
6KNSAKiniksa Pharmaceuticals International Plc2.38%33,785$3.17M97
7ADMAADMA Biologics Inc2.04%213,528$2.72M114
8BGNEBeOne Medicines Ltd2.02%6,628$2.7M1
9ZLABZai Lab Ltd1.96%102,699$2.62M14
10HALOHalozyme Therapeutics Inc1.96%25,224$2.61M225
11REGNRegeneron Pharmaceuticals Inc1.94%2,863$2.59M428
12GILDGilead Sciences Inc1.75%13,958$2.33M497
13EXELExelixis Inc1.72%32,996$2.3M256
14AMGNAmgen Inc1.71%4,935$2.27M507
15ZYMEZymeworks Inc1.70%76,620$2.27M67

Showing 1–15 of 66 holdings

BBP Performance

Launched Dec 16, 2014

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

BBP$14,118
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,339
Nov 7, 2025 to Nov 9, 2026. BBP $14,118. SPY $11,339. Use the arrow keys to read each point.$10,000$12,000$14,000Nov 2025May 2026Nov 2026

Nov 7, 2025 – Nov 9, 2026

Returns run to the Nov 9, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BBP. Periods over one year show the average yearly return.
PeriodBBP
Year to date+30.8%
1 month−0.2%
3 months+4.1%
1 year+41.2%
3 yearsper year+30.7%
5 yearsper year+15.2%
10 yearsper year+12.0%

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BBP
YearReturn barBBP
2026 YTD+30.8%
2025+33.1%
2024+3.3%
2023+17.9%
2022+0.9%
2021−8.2%
2020+22.2%

BBP in the news

BBP Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Nov 9, 2026.
0.00%Last 12 months
Payout per share
NoneLast 12 months

No distributions in the last 12 months.

Distribution history

Payments through 2017

One bar per payment. 2 payments from 2015 to 2017. Dec 21, 2015 $0.40; Dec 20, 2017 $0.07. Use the arrow keys to read each point.201520162017
Ex-datePay dateAmount per share
Dec 20, 2017Dec 27, 2017$0.07
Dec 21, 2015Dec 29, 2015$0.40

$10,000 in BBP 10 years ago paid $20.55 in dividends.

BBP Risk

Risk pillarB66 out of 100Rank 8 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
18.7%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.30
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−33.6%
Trough May 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.71
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

BBP Cost

Compare BBP and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$2,980

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BBP 0.34%

    $6,932

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • BBP 0.34%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K051015202530BBP $6,932IBBQ $3,952

Year by year

YearBBPIBBQOverpaying
10$616$347$269
20$2,386$1,351$1,035
30$6,932$3,952$2,980

Other funds in Biotech & Genomics

See others